Alembic Pharmaceuticals Intrinsic Value
Alembic Pharmaceuticals intrinsic value. Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹2099.20 from 10 valuation models (range ₹436–₹2624), vs current price ₹1049.60 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Alembic Pharmaceuticals screener.
APLLTD Valuation Methods Summary — DCF, Graham Number & P/E
Alembic Pharmaceuticals intrinsic value across 10 models vs current price ₹1049.60 — upside/downside and value range per method. Analyse Alembic Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1500.40 | ₹1200.32 - ₹1800.48 | +42.9% | EPS: ₹68.20, Sector P/E: 22x |
| Book Value Method | asset | ₹2624.00 | ₹2361.60 - ₹2886.40 | +150.0% | Book Value/Share: ₹1453.59, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2099.20 | ₹1889.28 - ₹2309.12 | +100.0% | Revenue/Share: ₹2686.15, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2099.20 | ₹1889.28 - ₹2309.12 | +100.0% | EBITDA: ₹2308.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2186.56 | ₹1749.25 - ₹2623.87 | +108.3% | CF Growth: 9.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹436.48 | ₹392.83 - ₹480.13 | -58.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1053.69 | ₹948.32 - ₹1159.06 | +0.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2099.20 | ₹1889.28 - ₹2309.12 | +100.0% | ROE: 23.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1493.50 | ₹1344.15 - ₹1642.85 | +42.3% | EPS: ₹68.20, BVPS: ₹1453.59 |
| Dividend Yield Method | dividend | ₹480.00 | ₹432.00 - ₹528.00 | -54.3% | DPS: ₹12.00, Target Yield: 2.5% |
APLLTD Intrinsic Value vs Market Price — All Valuation Models
Alembic Pharmaceuticals fair value range ₹436–₹2624 vs current market price ₹1049.60 across 10 valuation models. Browse Alembic Pharmaceuticals annual reports for revenue, profit, balance sheet and cash flow data.
APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?
Alembic Pharmaceuticals median intrinsic value ₹2099.20, current price ₹1049.60 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of APLLTD?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹2099.20 (median value). With the current market price of ₹1049.60, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹436.48 to ₹2624.00, indicating ₹436.48 - ₹2624.00.
Is APLLTD undervalued or overvalued?
Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 100.0%.
APLLTD Financial Health — Key Ratios vs Industry Benchmarks
Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 23.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.20x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
APLLTD Cash Flow Quality — Operating & Free Cash Flow
Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹783 Cr | ₹530 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹88 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹803 Cr | ₹643 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹724 Cr | ₹500 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹552 Cr | ₹366 Cr | Positive Free Cash Flow | 8/10 |